Ann: Intention to launch Share Purchase Plan, page-59

I was just trying to correct/get a re-think on the way EV was being calculated. I am not focused on the EV personally.

For me, EV / MC is a piece of the puzzle for investors, as smart investors will get nervous when funds in the bank are short.

That said, I am focused on key drivers / overall picture:

1. we are funded to the end of these trails
2. we have timelines (around this time next year for the news from the trails) - July 2024 approx
3. the drug works by itself and/or in combination with other drugs/therapies
4. fast track approval as a break through drug is possible once the trials complete and confirm the findings in previous trials
5. potential in both stages of DMD - ambulatory and non ambulatory boys
6. inflammation is the key cause of so much! Potentially can be used on other illnesses - increasing the ability to earn dollars. DMD patients are estimated to need to spend $200K per year per person.

I wish I could fast forward two years into the future!